# AEON Biopharma, Inc.: financial statements, quarterly

AEON · NYSE · CIK 1837607 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aeon.md) · [Financials](/companies/aeon/financials.md) · [Filings](/companies/aeon/filings.md) · [Insiders](/companies/aeon/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aeon/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-06-30) | Q3 FY2024 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [9.0](/filings/0001558370-24-011896.md) | not reported | [5.7](/filings/0001837607-25-000050.md) | [4.4](/filings/0001837607-25-000066.md) | [1.0](/filings/0001837607-25-000085.md) | [3.0 d](/filings/0001837607-26-000019.md) | [0.8](/filings/0001837607-26-000042.md) | [1.1](/filings/0001837607-26-000062.md) | [0.6](/filings/0001837607-25-000085.md) | [1.6 d](/filings/0001837607-26-000019.md) | [2.0](/filings/0001837607-26-000042.md) | [2.9](/filings/0001837607-26-000062.md) |
| Selling, general and administrative | $m | [4.9](/filings/0001558370-24-011896.md) | not reported | [4.6](/filings/0001837607-25-000050.md) | [3.3](/filings/0001837607-25-000066.md) | [3.0](/filings/0001837607-25-000085.md) | [2.6 d](/filings/0001837607-26-000019.md) | [3.1](/filings/0001837607-26-000042.md) | [3.3](/filings/0001837607-26-000062.md) | [1.9](/filings/0001837607-25-000085.md) | [3.9 d](/filings/0001837607-26-000019.md) | [3.9](/filings/0001837607-26-000042.md) | [3.0](/filings/0001837607-26-000062.md) |
| Operating income | $m | [(14.0)](/filings/0001558370-24-011896.md) | not reported | [(74.2)](/filings/0001837607-25-000050.md) | [153](/filings/0001837607-25-000066.md) | [(4.0)](/filings/0001837607-25-000085.md) | [(2.3) d](/filings/0001837607-26-000019.md) | [(0.5)](/filings/0001837607-26-000042.md) | [(4.3)](/filings/0001837607-26-000062.md) | [(2.5)](/filings/0001837607-25-000085.md) | [(5.5) d](/filings/0001837607-26-000019.md) | [(5.9)](/filings/0001837607-26-000042.md) | [(5.9)](/filings/0001837607-26-000062.md) |
| Income tax | $m | [0.1](/filings/0001104659-23-082959.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(15.4)](/filings/0001558370-24-011896.md) | [(27.7) d](/filings/0001837607-24-000014.md) | [(118)](/filings/0001837607-25-000050.md) | [164](/filings/0001837607-25-000066.md) | [(6.2)](/filings/0001837607-25-000085.md) | [2.1 d](/filings/0001837607-26-000019.md) | [9.1](/filings/0001837607-26-000042.md) | [(6.6)](/filings/0001837607-26-000062.md) | [(4.5)](/filings/0001837607-25-000085.md) | [(37.1) d](/filings/0001837607-26-000019.md) | [(11.8)](/filings/0001837607-26-000042.md) | [(1.2)](/filings/0001837607-26-000062.md) |
| Diluted EPS | $ per share | [(0.11)](/filings/0001558370-24-011896.md) | not reported | [(227.87)](/filings/0001837607-25-000050.md) | [304.00](/filings/0001837607-25-000066.md) | [(11.24)](/filings/0001837607-25-000085.md) | not reported | [2.28](/filings/0001837607-26-000042.md) | [(0.60)](/filings/0001837607-26-000062.md) | [(0.39)](/filings/0001837607-25-000085.md) | not reported | [(0.29)](/filings/0001837607-26-000042.md) | [(0.02)](/filings/0001837607-26-000062.md) |
| Basic EPS | $ per share | [(0.11)](/filings/0001558370-24-011896.md) | not reported | [(227.87)](/filings/0001837607-25-000050.md) | [304.00](/filings/0001837607-25-000066.md) | [(11.24)](/filings/0001837607-25-000085.md) | not reported | [2.28](/filings/0001837607-26-000042.md) | [(0.60)](/filings/0001837607-26-000062.md) | [(0.39)](/filings/0001837607-25-000085.md) | not reported | [(0.29)](/filings/0001837607-26-000042.md) | [(0.02)](/filings/0001837607-26-000062.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-09-30) | FY2024 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.2](/filings/0001837607-24-000014.md) | [5.2](/filings/0001837607-25-000022.md) | [1.6](/filings/0001837607-24-000063.md) | [3.4](/filings/0001558370-24-011896.md) | [0.5](/filings/0001837607-24-000093.md) | [0.0](/filings/0001837607-26-000019.md) | [10.4](/filings/0001837607-25-000050.md) | [8.4](/filings/0001837607-25-000066.md) | [5.9](/filings/0001837607-25-000085.md) | [3.0](/filings/0001837607-26-000062.md) | [6.2](/filings/0001837607-26-000042.md) | [3.4](/filings/0001837607-26-000062.md) |
| Current assets | $m | [16.9](/filings/0001837607-24-000014.md) | [6.2](/filings/0001837607-25-000022.md) | [2.5](/filings/0001837607-24-000063.md) | [4.0](/filings/0001558370-24-011896.md) | [2.4](/filings/0001837607-24-000093.md) | [1.6](/filings/0001837607-26-000019.md) | [12.3](/filings/0001837607-25-000050.md) | [10.3](/filings/0001837607-25-000066.md) | [7.4](/filings/0001837607-25-000085.md) | [3.4](/filings/0001837607-26-000062.md) | [6.6](/filings/0001837607-26-000042.md) | [4.0](/filings/0001837607-26-000062.md) |
| Total assets | $m | [17.6](/filings/0001837607-24-000014.md) | [6.8](/filings/0001837607-25-000022.md) | [3.0](/filings/0001837607-24-000063.md) | [5.7](/filings/0001558370-24-011896.md) | [4.0](/filings/0001837607-24-000093.md) | [3.1](/filings/0001837607-26-000019.md) | [13.8](/filings/0001837607-25-000050.md) | [11.7](/filings/0001837607-25-000066.md) | [8.7](/filings/0001837607-25-000085.md) | [5.6](/filings/0001837607-26-000062.md) | [8.6](/filings/0001837607-26-000042.md) | [5.9](/filings/0001837607-26-000062.md) |
| Current liabilities | $m | [14.2](/filings/0001837607-24-000014.md) | [13.0](/filings/0001837607-25-000022.md) | [16.0](/filings/0001837607-24-000063.md) | [10.4](/filings/0001558370-24-011896.md) | [10.7](/filings/0001837607-24-000093.md) | [14.1](/filings/0001837607-26-000019.md) | [8.6](/filings/0001837607-25-000050.md) | [9.1](/filings/0001837607-25-000066.md) | [8.2](/filings/0001837607-25-000085.md) | [6.9](/filings/0001837607-26-000062.md) | [6.7](/filings/0001837607-26-000042.md) | [7.3](/filings/0001837607-26-000062.md) |
| Total liabilities | $m | [146](/filings/0001837607-24-000014.md) | [160](/filings/0001837607-25-000022.md) | [201](/filings/0001837607-24-000063.md) | [33.7](/filings/0001558370-24-011896.md) | [36.1](/filings/0001837607-24-000093.md) | [31.7](/filings/0001837607-26-000019.md) | [25.1](/filings/0001837607-25-000050.md) | [27.5](/filings/0001837607-25-000066.md) | [28.6](/filings/0001837607-25-000085.md) | [60.6](/filings/0001837607-26-000062.md) | [25.4](/filings/0001837607-26-000042.md) | [21.3](/filings/0001837607-26-000062.md) |
| Shareholders' equity | $m | [(128)](/filings/0001837607-24-000014.md) | [(153)](/filings/0001837607-25-000085.md) | [(198)](/filings/0001837607-25-000066.md) | [(27.9)](/filings/0001837607-25-000085.md) | [(32.1)](/filings/0001837607-25-000085.md) | [(28.6)](/filings/0001837607-26-000062.md) | [(11.3)](/filings/0001837607-26-000062.md) | [(15.9)](/filings/0001837607-26-000062.md) | [(19.9)](/filings/0001837607-25-000085.md) | [(55.0)](/filings/0001837607-26-000062.md) | [(16.8)](/filings/0001837607-26-000062.md) | [(15.4)](/filings/0001837607-26-000062.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-03-31) | Q2 FY2024 (2023-06-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.1)](/filings/0001837607-24-000063.md) | [(10.1) d](/filings/0001558370-24-011896.md) | [(8.6)](/filings/0001837607-25-000050.md) | [(8.1) d](/filings/0001837607-25-000066.md) | [(3.0) d](/filings/0001837607-25-000085.md) | [(0.6) d](/filings/0001837607-26-000019.md) | [(7.9)](/filings/0001837607-26-000042.md) | [(2.1) d](/filings/0001837607-26-000062.md) | [(2.6) d](/filings/0001837607-25-000085.md) | [(4.7) d](/filings/0001837607-26-000019.md) | [(2.6)](/filings/0001837607-26-000042.md) | [(3.7) d](/filings/0001837607-26-000062.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001837607-26-000042.md) | [0.0 d](/filings/0001837607-26-000062.md) | [0.0 d](/filings/0001837607-25-000085.md) | [0.0 d](/filings/0001837607-26-000019.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2024 (2023-03-31) | Q2 FY2024 (2023-06-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [139](/filings/0001837607-24-000014.md) | [139](/filings/0001837607-24-000063.md) | [139](/filings/0001558370-24-011896.md) | [0.5](/filings/0001837607-25-000050.md) | [0.5](/filings/0001837607-25-000066.md) | [0.5](/filings/0001837607-25-000085.md) | [4.0](/filings/0001837607-26-000042.md) | [11.1](/filings/0001837607-26-000062.md) | [11.6](/filings/0001837607-25-000085.md) | [40.6](/filings/0001837607-26-000042.md) | [50.5](/filings/0001837607-26-000062.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,882,790 at 2026-08-06, from the cover of the [10-Q filed 2026-08-12](/filings/0001837607-26-000062.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.